{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:46:18Z","timestamp":1773294378972,"version":"3.50.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/jcp.0b013e31820e3d9d","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T08:21:14Z","timestamp":1298449274000},"page":"169-173","source":"Crossref","is-referenced-by-count":15,"title":["Does Switching to Another Antipsychotic in Patients With Clozapine-Associated Granulocytopenia Solve the Problem?"],"prefix":"10.1097","volume":"31","author":[{"given":"Beh\u00e7et","family":"Co\u015far","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa Ender","family":"Taner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hale Yapc","family":"Eser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Ercan","family":"Altn\u00f6z","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rfat","family":"Tarhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis-incidence and risk factors in the United States.","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.169.4.483","article-title":"Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.","volume":"169","author":"Atkin","year":"1996","journal-title":"Br J Psychiatry"},{"issue":"10","key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5694\/j.1326-5377.1998.tb141414.x","article-title":"Clozapine treatment in Australia: a review of haematological monitoring.","volume":"168","author":"Copolov","year":"1998","journal-title":"Med J Aust"},{"issue":"suppl 9","key":"R4-6-20210128","first-page":"25","article-title":"Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.","volume":"63","author":"Meltzer","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/026988119801200309","article-title":"Haematological safety of antipsychotic drugs.","volume":"12","author":"King","year":"1998","journal-title":"J Psychopharmacol"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hup.917","article-title":"Haematological toxicity of drugs used in psychiatry.","volume":"23","author":"Flanagan","year":"2008","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"4","key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-2007-979222","article-title":"Two cases of olanzapine-induced reversible neutropenia.","volume":"32","author":"Steinwachs","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/01.jcp.0000117428.05703.16","article-title":"Olanzapine-induced neutropenia: mechanism and treatment.","volume":"24","author":"Duggal","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.psy.41.2.150","article-title":"Olanzapine-induced neutropenia.","volume":"41","author":"Gajwani","year":"2000","journal-title":"Psychosomatics"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4088\/JCP.v61n1111b","article-title":"Olanzapine induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric Institution.","volume":"61","author":"Teter","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/1531-8257(199909)14:5<872::AID-MDS1026>3.0.CO;2-Y","article-title":"Reversible leukopenia related to olanzapine.","volume":"5","author":"Meissner","year":"1999","journal-title":"Mov Disord"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.pnpbp.2005.04.025","article-title":"Olanzapine-induced leucopenia and neutropenia.","volume":"29","author":"Stergiou","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(99)03111-6","article-title":"Olanzapine induced agranulocytosis.","volume":"354","author":"Naumann","year":"1999","journal-title":"Lancet"},{"issue":"suppl 1","key":"R14-6-20210128","first-page":"S93","article-title":"Olanzapine-induced agranulocytosis.","volume":"3","author":"Tolosa-Villela","year":"2000","journal-title":"Int J Neuropsychopharmacol"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.genhosppsych.2006.10.011","article-title":"Olanzapine-induced agranulocytosis in systemic lupus erythematosus:a case report.","volume":"29","author":"Su","year":"2007","journal-title":"General Hospital Psychiatry"},{"issue":"4","key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/15622970410029938","article-title":"Reversible neutropenia during treatment with olanzapine: three case reports.","volume":"5","author":"Cordes","year":"2004","journal-title":"World J Biol Psychiatry"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0278-5846(01)00258-5","article-title":"Olanzapine-induced agranulocytosis A case report and review of the literature.","volume":"26","author":"Tolosa-Villela","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.pnpbp.2005.11.032","article-title":"Prolongation of clozapine-induced leukopenia with olanzapine treatment.","volume":"30","author":"Sayin","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00004850-200103000-00007","article-title":"Dose dependent olanzapine-associated leukopenia: three case reports.","volume":"16","author":"Kodesh","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/00048670601109980","article-title":"Prolongation of clozapine-induced neutropenia with olanzapine.","volume":"41","author":"Jagadheesan","year":"2007","journal-title":"Aust N Z J Psychiatry"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00004714-199712000-00014","article-title":"Prolongation of clozapine-induced granulocytopenia associated with olanzapine.","volume":"17","author":"Flynn","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(99)00957-5","article-title":"Olanzapine-induced neutropenia after clozapine-induced neutropenia.","volume":"354","author":"Benedetti","year":"1999","journal-title":"Lancet"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/00004714-200012000-00020","article-title":"Olanzapine prolongation of granulocytopenia after clozapine discontinuation.","volume":"20","author":"Konakanchi","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"872","DOI":"10.4088\/JCP.v61n1111b","article-title":"Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.","volume":"61","author":"Teter","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"R25-6-20210128","first-page":"591","article-title":"Olanzapine after clozapine: the rare case of prolongation of granulocytopaenia.","volume":"32","author":"Lambert","year":"1998","journal-title":"Aust N Z J Psychiatry"},{"issue":"2","key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4088\/JCP.v60n0209","article-title":"Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.","volume":"60","author":"Swartz","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00004850-200015040-00008","article-title":"Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone.","volume":"15","author":"Dernovsek","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"R28-6-20210128","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1176\/appi.ajp.162.2.397","article-title":"Risperidone-induced morning pseudoneutropenia.","volume":"162","author":"Esposito","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/15622970310029918","article-title":"Morning pseudoneutropenia during clozapine treatment.","volume":"4","author":"Esposito","year":"2003","journal-title":"World J Biol Psychiatry"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eurpsy.2003.03.009","article-title":"Risperidone-induced leucopenia and neutropenia: a case report.","volume":"19","author":"Sluys","year":"2004","journal-title":"Eur Psychiatry"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1192\/bjp.171.4.393d","article-title":"Risperidone-induced leucopenia and neutropenia.","volume":"171","author":"Dernovsek","year":"1997","journal-title":"Br J Psychiatry"},{"key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1176\/ajp.155.6.855a","article-title":"Risperidone-associated agranulocytosis.","volume":"155","author":"Finkel","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0924-977X(96)00024-7","article-title":"Risperidone and reversible neutropenia: a negative rechallenge.","volume":"6","author":"Bondolfi","year":"1996","journal-title":"Eur Neuropsychopharmacol"},{"key":"R34-6-20210128","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1176\/appi.ajp.158.10.1736-a","article-title":"Agranulocytosis and neutropenia with typical and atypical neuroleptics.","volume":"158","author":"Hong","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R35-6-20210128","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1176\/ajp.153.5.735b","article-title":"Agranulocytosis after addition of risperidone to clozapine treatment.","volume":"153","author":"Godleski","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"11","key":"R36-6-20210128","first-page":"1122","article-title":"Risperidone induced cytopenias.","volume":"48","author":"Biswas","year":"2000","journal-title":"J Assoc Physicians India"},{"issue":"6","key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/JCP.0b013e31818b53a1","article-title":"Leucopenia during therapy with risperidone long-acting injectable two case reports.","volume":"28","author":"Uzun","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R38-6-20210128","first-page":"78","article-title":"Ziprasidone related agranulocytosis following olanzapine induced neutropenia.","volume":"28","author":"Montgomery John","year":"2006","journal-title":"Gen Hosp Psychiatry"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1176\/appi.psy.48.6.530","article-title":"Quetiapine-induced leucopenia and thrombocytopenia.","volume":"48","author":"Shankar","year":"2007","journal-title":"Psychosomatics"},{"key":"R40-6-20210128","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pnpbp.2006.07.003","article-title":"Leukopenia and neutropenia induced by quetiapine.","volume":"31","author":"Cowan","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R41-6-20210128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1176\/appi.ajp.158.5.817","article-title":"Quetiapine and leucopenia.","volume":"158","author":"Clark","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R42-6-20210128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00004850-200403000-00007","article-title":"Experience of maintaining clozapine medication in patients with 'red-alert zone' neutropenia: long-term follow-up results.","volume":"19","author":"Ahn","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"R43-6-20210128","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.779","article-title":"Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS?","volume":"21","author":"Kang","year":"2006","journal-title":"Hum Psychopharmacol"},{"key":"R44-6-20210128","first-page":"429","article-title":"Clozapine-induced transient white blood count disorders.","volume":"55","author":"Hummer","year":"1994","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"R45-6-20210128","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4088\/JCP.v61n1204","article-title":"Switching clozapine responders to olanzapine.","volume":"61","author":"Littrell","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R46-6-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0447.2001.00429.x","article-title":"Agranulocytosis and granulocytopenia associated with quetiapine.","volume":"104","author":"Ruhe","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"R47-6-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1034\/j.1600-0447.2000.102002153.x","article-title":"Granulocyte colony-stimulating factor plasma levels during clozapine and olanzapine-induced granulocytopenia.","volume":"102","author":"Schuld","year":"2000","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"R48-6-20210128","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0026-895X(24)13269-5","article-title":"A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo.","volume":"53","author":"Gardner","year":"1998","journal-title":"Mol Pharmacol"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e31820e3d9d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T22:43:33Z","timestamp":1740955413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201104000-00006"}},"subtitle":["Case Series of 18 Patients"],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31820e3d9d","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}